Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Soleno Therapeutics Faces Securities...
Regulatory securities lawsuit

Soleno Therapeutics Faces Securities Fraud Lawsuit

Analysis based on 180 articles · First reported Mar 09, 2026 · Last updated Apr 17, 2026

Sentiment
-30
Attention
2
Articles
180
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of a securities fraud lawsuit against Soleno Therapeutics, as it suggests potential financial liabilities and a loss of investor confidence. This event could lead to a decrease in Soleno Therapeutics' stock price and increased scrutiny on its drug development programs.

Biotechnology Legal Services
Event Summary

Rosen Law Firm and Kahn Swick & Foti are reminding investors of the May 5, 2026 lead plaintiff deadline for a class action securities lawsuit against Soleno Therapeutics. The lawsuit alleges that Soleno Therapeutics made false and misleading statements between March 26, 2025, and November 4, 2025, regarding its Phase 3 clinical trial program for diazoxide choline extended-release tablets (DCCR). Specifically, the lawsuit claims Soleno Therapeutics downplayed and concealed significant safety concerns related to DCCR, including issues of excess fluid retention in trial participants. This allegedly led to materially greater safety risks and lower commercial viability for DCCR than disclosed, impacting patient discontinuation rates, adoption, prescriber reluctance, and potentially leading to adverse regulatory action and reputational damage. Investors who purchased Soleno Therapeutics common stock during the specified period may be entitled to compensation.

Key Actions
100 Soleno Therapeutics allegedly made false and misleading statements
90 Soleno Therapeutics made false and/or misleading statements
90 Rosen Law Firm initiated class action lawsuit Soleno Therapeutics
90 Rosen Law Firm filed class action lawsuit Soleno Therapeutics
85 Kahn Swick & Foti notified investors of class action lawsuit Soleno Therapeutics
Entities Involved
stock
Soleno Therapeutics
Soleno Therapeutics is facing a class action lawsuit for allegedly making false and misleading statements regarding the safety and commercial viability of its drug DCCR. This could lead to significant financial penalties and reputational damage.
Importance 100 Sentiment -70
subs
Soleno Therapeutics===DCCR
Soleno Therapeutics===DCCR is Soleno Therapeutics' drug candidate for treating hyperphagia in individuals with PWS. It is at the center of the controversy due to alleged safety concerns, including excess fluid retention, and questions about its commercial viability.
Importance 85 Sentiment -60
priv
Rosen Law Firm
Rosen Law Firm is actively seeking lead plaintiffs for a class action lawsuit against Soleno Therapeutics, alleging securities fraud. This action could enhance their reputation in securities litigation.
Importance 80 Sentiment 50
priv
Hagens Berman
Hagens Berman, a national shareholders rights firm, has filed a securities class action lawsuit against Soleno Therapeutics and is investigating potential violations of federal securities laws. The firm is encouraging investors with losses to contact them.
Importance 80 Sentiment 70
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is the law firm that filed the class action lawsuit against Soleno Therapeutics, seeking to recover damages for investors. This action enhances the firm's reputation as an investor-rights law firm.
Importance 80 Sentiment 60
priv
Kessler Topaz Meltzer & Check
Kessler Topaz Meltzer & Check, LLP is a law firm informing investors about the class action lawsuit against Soleno Therapeutics and encouraging affected investors to contact them to discuss legal rights and lead plaintiff status.
Importance 80 Sentiment 20
subs
Soleno Therapeutics===DCCR
Soleno Therapeutics===DCCR is Soleno Therapeutics' drug candidate for treating hyperphagia in individuals with Prader-Willi syndrome. It is at the center of the lawsuit due to alleged undisclosed safety concerns, including excess fluid retention and a patient death, which have negatively impacted its commercial viability.
Importance 80 Sentiment -80
+ 18 more entities View on Dashboard
Relationships
Rosen Law Firm related ↔ Soleno Therapeutics
Kahn Swick & Foti related ↔ Soleno Therapeutics
Charles Foti related ↔ Kahn Swick & Foti
United States===City of Pontiac Police and Fire Retirement System related ↔ Soleno Therapeutics
Rosen Law Firm related ↔ Kahn Swick & Foti
Hagens Berman related ↔ Soleno Therapeutics
Reed Kathrein related ↔ Hagens Berman
Soleno Therapeutics related ↔ Scorpion Capital
Hagens Berman related ↔ Scorpion Capital
Lewis Kahn related ↔ Kahn Swick & Foti
+ 18 more relationships View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.